# A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

> **NCT03856996** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 30 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** Stable CH505TF gp120
- **BIOLOGICAL:** Transient CH505TF gp120
- **BIOLOGICAL:** Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)

## Key facts

- **NCT ID:** NCT03856996
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-23
- **Primary completion:** 2021-03-16
- **Final completion:** 2021-09-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856996, "A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03856996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*